from OncLive by Anita T. Shaffer – The optimal use of emerging assays that characterize molecular abnormalities from plasma in late-stage non–small cell lung cancer (NSCLC) will be to augment tissue biopsies at initial diagnosis and to evaluate patients for ...
Read More »